Comparison

Pazufloxacin (mesylate) European Partner

Item no. HY-B0724A-500mg
Manufacturer MedChem Express
CASRN 163680-77-1
Amount 500 mg
Quantity options 100 mg 10 mM/1 mL 500 mg
Category
Type Inhibitors
Specific against other
Purity 99.97
Citations [1]Fukuoka, Y., et al., In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother, 1993. 37(3): p. 384-92.|[2]Muratani, T., M. Inoue, and S. Mitsuhashi, In vitro activity of T-3761, a new fluoroquinolone. Antimicrob Agents Chemother, 1992. 36(10): p. 2293-303.
Smiles O=C(C(C1=O)=CN2[C@@H](C)COC3=C(C4(N)CC4)C(F)=CC1=C23)O.CS(=O)(O)=O
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias T-3762,Pazufloxacin methanesulfonate,Pazufloxacin mesilate
Shipping Condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
COVID-19-immunoregulation
Manufacturer - Targets
Antibiotic; Bacterial
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Molecular Weight
414.41
Product Description
Pazufloxacin (T-3761) mesylate is a fluoroquinolone antibiotic.Target: AntibacterialPazufloxacin (T-3761), a new quinolone derivative, showed broad and potent antibacterial activity. T-3761 showed good efficacy in mice against systemic, pulmonary, and urinary tract infections with gram-positive and gram-negative bacteria, including quinolone-resistant Serratia marcescens and Pseudomonas aeruginosa. The in vivo activity of T-3761 was comparable to or greater than those of ofloxacin, ciprofloxacin, norfloxacin, and tosufloxacin against most infection models in mice. The activities of T-3761 were lower than those of tosufloxacin against gram-positive bacterial systemic and pulmonary infections in mice but not against infections with methicillin-resistant Staphylococcus aureus [1]. T-3761 had a broad spectrum of activity and had potent activity against gram-positive and -negative bacteria. The MICs of T-3761 against 90% of the methicillin-susceptible Staphylococcus aureus, methicillin-susceptible and -resistant Staphylococcus epidermidis, and Clostridium spp. tested were 0.39 to 6.25 micrograms/ml. The MBCs of T-3761 were either equal to or twofold greater than the MICs. The 50% inhibitory concentrations of T-3761 for DNA gyrases isolated from E. coli and P. aeruginosa were 0.88 and 1.9 micrograms/ml, respectively [2].
Manufacturer - Research Area
Infection
Solubility
DMSO: 100 mg/mL (ultrasonic)|H2O: ≥ 100 mg/mL
Manufacturer - Pathway
Anti-infection
Isoform
Quinolone
Clinical information
Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close